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Background: Glucocorticoid excess is commonly associated with diabetogenic effects, including insulin resistance
and glucose intolerance. The effects of the long-term glucagon-like peptide 1 receptor agonist treatment on the
metabolic syndrome-like conditions are not yet fully elucidated. Thus, we aimed to test whether long-term liraglutide
treatment could be effective as a therapy to counteract the metabolic dysfunctions induced by chronic glucocorticoid
exposure.
Methods: Mice were given corticosterone or vehicle via their drinking water for five consecutive weeks. In addition,
mice were treated with once-daily injections of either PBS or liraglutide.
Results: Liraglutide treatment slowed progression towards obesity and ectopic fat deposition in liver that otherwise
occurred in corticosterone-treated mice. The drug reduced the increment in serum insulin caused by corticosterone,
but did not affect the reduction of insulin sensitivity. Furthermore, liraglutide improved glucose control in mice
exposed to corticosterone as evident by a delay in the progression towards post-prandial hyperglycemia and enhanced
glucose clearance during a glucose tolerance test. Glucose-stimulated C-peptide levels were higher in those mice that
had received liraglutide and corticosterone compared to mice that had been treated with corticosterone alone,
indicating a positive role of liraglutide for beta-cell function. Morphometric analysis revealed increased beta- and
alpha-cell masses that were associated with more Ki67-positive islet cells in corticosterone-treated mice irrespective of
whether they were co-treated with liraglutide or not. Liraglutide had no discernible effect on alpha-cell mass.
Conclusion: Liraglutide can be beneficial for subjects at risk of developing metabolic complications as a result of
glucocorticoid excess.
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During long term treatment with glucocorticoids (GCs),
many patients develop various degrees of glucose in-
tolerance, some progressing into frank diabetes, a condi-
tion commonly known clinically as “steroid diabetes” [1].
Additionally, worsening of glycemic control in patients
with known type 2 diabetes mellitus (T2DM) on GC
therapy is also a clinically well-known phenomenon. The
reasons for the impaired glucose tolerance are probably* Correspondence: henrik.ortsater@ki.se
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stated.multifactorial, and the precise nature of the mechanisms
contributing remains elusive. The insulin-producing
pancreatic beta-cell may be extra susceptible to GC ex-
cess, since both iatrogenic Cushing syndrome and GC-
induced diabetes in animal models are associated with
loss of glucose-stimulated insulin secretion (GSIS), and
GC immunosuppressive treatment adversely affects islet
transplantation outcome [2]. In animal models suscep-
tible to GC treatment, dexamethasone exposure causes
GLUT-2 degradation, thereby impeding beta-cell glucose
sensing [3] and increases islet glucose cycling as a conse-
quence of augmented glucose-6-phosphatase activity [4,5].
In vitro, GCs exert several negative effects on beta-cell
function including reduced GSIS and increased alpha-2al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Kv1.5 channel (repolarizing potassium channel) [7], endo-
plasmic reticulum dysfunction [8], and increased beta-cell
apoptosis [9,10]. Since the human insulin gene contains
GC-sensitive transcriptional elements [11], it may be sus-
ceptive to deleterious effects of GCs. Beta-cell susceptibil-
ity to GCs may also be relevant in the natural unfolding
of diabetes, since mice overexpressing the GC recep-
tor restricted to the beta-cell develop early beta-cell fail-
ure, glucose intolerance and later in life overt diabetes
[4,5]. Humans with impaired beta-cell function (low insu-
lin responders) are predisposed to become overtly dia-
betic during GC therapy [12]. Clinically, steroid diabetes
or worsened glycemic control in diabetic subjects is usu-
ally treated with insulin injections, oftentimes mixtures
containing a high proportion of a direct acting insulin
analogue to curb prandial glycemia. However, such regime
may result in undesirable side effects. The risk of incur-
ring hypoglycemia, weight gain and adiposity – on top of
what is the result of GC therapy – is a significant draw-
back of insulin treatment. Recently, another class of anti-
diabetic agents, incretin-based therapy, has been made
available [13,14]. This novel treatment modality is based
upon activation of the receptor for glucagon-like peptide
1 (GLP-1), which leads to enhanced GSIS, glucagon sup-
pression and other antidiabetic effects [13,14]. GLP-1 is
synthesized in enteroendocrine L-cells and is released
post-prandially in proportion to caloric intake. Especially
carbohydrate and fat seem to be effective stimuli for GLP-
1 secretion [15]. GLP-1 drugs, in contrast to insulin, are
devoid of risk for hypoglycemia and weight gain. Exendin-
4, the first generation GLP-1 receptor (GLP-1R) agonist
was recently shown to improve beta-cell function in
healthy men treated for two days with prednisolone [16].
Similarly, Matsuo et al. reported on four cases of patients
with type 2 diabetes with worsened glycemic control due
to GCs who were successfully treated with exendin-4 ad-
ministration [17]. Although these studies indicate benefi-
cial glycemic effects of GLP-1 receptor activation after GC
treatment, they neither address the ability of these drugs
to counteract the long-term effects of GC treatment. In
the present work, we aimed at addressing this issue in an
animal model of steroid diabetes by using liraglutide, an
efficacious second generation GLP-1 analogue in clinical
use [18,19] and to study the mechanisms behind any pro-
tective effect exerted by liraglutide.
Methods
Animals and treatment
Experiments were performed on 8-week-old male C57Bl/6J
mice (Nova, Sollentuna Sweden) which were fed ad libitum
and housed in 12 hours of light/12 hours of dark cycles.
The study was performed according to the guidelines of
Karolinska Institutet and approved by the Stockholm Southanimal ethics committee (S49-12). Animals were ran-
domly assigned to either receive corticosterone (100 μg/ml,
[Sigma, St Louis, MO, USA]) or vehicle (1% ethanol) via
their drinking water. This corticosterone regimen is known
to produce a valuable mouse model with metabolic syn-
drome features [20,21]. In addition, half of the mice in each
group were given once daily s.c. injections (between 9:00
and 10:00 am) of liraglutide (Novo Nordisk A/S, Bagsvaerd,
Denmark) and the other half were given PBS in the same
manner. To improve liraglutide tolerability, the drug was
given in escalating doses starting at 0.15 mg per kg body
weight with a daily increment of 0.025 mg/kg until the
final dose of 0.3 mg per kg body weight was reached. This
dose was maintained during the remaining part of the
study period.
Food intake, body weight, and blood glucose levels in
random-fed mice were monitored weekly, using a hand-
held glucometer (One-Touch Ultra 2; LifeScan, Milpitas,
CA, USA). Every week blood was collected for serum
insulin level evaluations with ELISA (Mercodia, Uppsala,
Sweden). Blood samples for determination of glucose
and insulin concentrations were taken in the morning in
non-fasted animals prior to administration of liraglutide
or PBS. The total exposure period was five weeks during
which the animals were subjected to insulin or glucose
tolerance tests (IPinsTT and IPGTT, respectively) as de-
scribed below. After the five weeks of treatment, mice
were sacrificed and organs were collected. Pancreatic
glands were dissected and fixated in 4% phosphate-
buffered paraformaldehyde, paraffin-embedded and sec-
tioned for immunohistochemistry. Fat deposits and spleen
were gently removed and weighed, and liver fragments
were snap-frozen for later sectioning and oil-red-O stain-
ing. Blood was collected by heart puncture for later
analyses of serum non-esterified fatty acids (NEFA), total
cholesterol and triglycerides (analyzed at Karolinska
University Laboratory at Södersjukhuset, Stockholm and
Center for Inherited Metabolic Diseases, Karolinska
University Hospital, Solna) and for corticosterone (cor-
ticosterone EIA, Enzo Life Sciences, Lausen, Switzerland)
and corticotropin (mouse corticotropin ELISA, Wuhan
EIAab Science, Wuhan, China).
IPinsTT and IPGTT
IPinsTT and IPGTT were performed during the fourth
and fifth week of treatment, respectively. For IPinsTT
and IPGTT, mice were fasted one or six hours, respect-
ively, and then injected IP with insulin (2 IU/kg body
weight) or glucose (1.5 g/kg body weight). On the day of
the tolerance tests, liraglutide was injected as usual in the
morning, 6 hours before the experiments. The fasting time
before the IPinsTT was kept short to avoid hypoglycemia
and counter regulatory hormone secretion. Mice received
the standard injections of PBS or liraglutide on the same
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cose was monitored before and after the insulin or glucose
injections. During the IPGTT blood was also collected
before and at 15 and 30 minutes post injection for deter-
mination of C-peptide levels, which were evaluated using
ELISA (Alpco Diagnostics, Salem, NH, USA).
Oil-red-O staining
Frozen fragments of liver were embedded in NEG-50
(Thermo Scientific, Waltham, MA, USA). Cryo-sections
(12 μm) were obtained from different parts of the tissues
and stained for neutral lipids using oil-red-O as previ-
ously described [22]. Quantification of lipid droplets was
done in accordance with [22].
Quantitative approaches in endocrine pancreas
To study the morphometric parameters of endocrine
pancreas, 5-6 pancreatic glands from each group were
excised and processed according to a previous descrip-
tion [23] except that 4% phosphate-buffered paraformal-
dehyde was used as fixative solution.
Immunostaining
Islet distribution of insulin, glucagon and Ki67 were ana-
lyzed as previously described [23].
Alpha- and beta-cell mass
Alpha-cell and beta-cell mass was determined by point
counting morphometry on each pancreas section immu-
nostained for either glucagon or insulin, as previously
described [24]. Each section was systematically scored
with a grid of 130 points (final magnification × 100) using
the image processing and analysis software - ImageJ (freely
available at http://rsbweb.nih.gov/ij/). The numbers of in-
tercepts over beta-cells, endocrine non-beta-cells and exo-
crine pancreatic tissue were counted. The beta-cell relative
volume was calculated by dividing the intercepts over
beta-cells by the intercepts over the total pancreatic tissue;
the beta-cell mass was then estimated by multiplying the
beta-cell relative volume by the total pancreas weight. The
same methodology was applied for counting alpha-cell
mass in sections immunostained for glucagon.
Islet-cell proliferation
Averaged islet-cell proliferation was obtained by counting
total islet-cell stained for insulin and Ki67 using the same
software cited above. All islets found in each pancreas sec-
tion were sampled (1,714 ± 218 beta-cell nuclei per group).
The rate of islet-cell proliferation was expressed as the
proportion of Ki67-positive cells of total islet cells [24].
Statistical analysis
Data are presented as mean ± s.e.m. The appropriate
t-test, or one-way ANOVA followed by Bonferroni post-hoc test, was used as required to identify differences be-
tween groups, using GraphPad Prism 5.0 software. A value
of p < 0.05 was considered statistically significant.
Results
Once daily injections of liraglutide delay body weight
gain and obesity in corticosterone-treated mice
The present study includes four different experimental
groups. Male C57Bl/6J mice were randomized to receive
either vehicle (1% ethanol) or 100 μg/ml of corticosterone
via their drinking water. In addition, both vehicle- and
corticosterone-treated mice were given once daily injec-
tions of either PBS or liraglutide (final dose 0.3 mg/kg
body weight). Vehicle-treated mice gained on average
2.5 ± 0.3 g weight over the five week study period. Mice
receiving corticosterone via their drinking water had an
augmented net body weight gain that was significant
already after two weeks of treatment (Figure 1A) and was
associated with a higher food intake (Figure 1B). Once
daily injections with liraglutide did not influence food in-
take or body weight gain in vehicle-treated animals, but
clearly slowed body weight gain in corticosterone-treated
mice (Figure 1A). As expected, administration of cortico-
sterone via the drinking water led to supraphysiological
levels of the steroid hormone and suppressed endogenous
levels of corticotropin (Table 1). Liraglutide treatment did
not modulate serum levels of corticosterone or cortico-
tropin neither in mice receiving vehicle nor cortico-
sterone. This model of GC excess develops enlarged fat
deposits and dyslipidemia (Figure 1C and Table 1). In con-
cordance with a reduced body weight gain, fat deposit
weights were generally lower in liraglutide-treated mice
(Figure 1C). In contrast, treatment with liraglutide had
minor, if any, effects on serum levels of NEFA, triglycer-
ides and total cholesterol (Table 1). Chronic treatment
with corticosterone is known to reduce spleen size [25]. In
vehicle-treated mice that had received injections of PBS
the spleen weight was 0.3 ± 0.04% of total body weight.
Treatment with corticosterone reduced spleen weight to
0.13 ± 0.01% of total body weight (p < 0.01). However,
once daily injections of liraglutide did not influence spleen
weight in either vehicle- or corticosterone-treated mice,
showing that liraglutide did not reduce corticosterone
effects in mice in general. As corticosterone-exposed
mice accumulate ectopic fat [26], which is known to con-
tribute to deranged glucose control [27], we also moni-
tored accumulation of neutral lipids in cryo-sections of
liver tissue via oil-red-O staining. Indeed, corticosterone-
treated mice had a 6.5-fold increase in liver oil-red-O
staining compared to vehicle-treated mice (Figures 1D
and E). While liraglutide had no effect on liver steatosis in
vehicle-treated mice, the drug reduced hepatic neutral
lipid content by approximately 40% in corticosterone-
treated mice (Figures 1D and E). In conclusion, once-daily
Figure 1 Once daily injections of liraglutide delay body weight gain and obesity in corticosterone-exposed mice. Male C57Bl/6J mice
were treated with 1% ethanol (Vehicle, white squares and circles or white bars) or 100 μg/ml corticosterone (GC, black squares and circles or
black bars) via the drinking water together with once-daily injections of either PBS (squares or unstriped bars) or liraglutide (Lira) at a final dose of
0.3 mg per kg body weight (circles or striped bars) for five consecutive weeks (n = 6). Body weight gain (A) and food intake (B) was determined
weekly, fat deposit size (C), and ectopic fat in liver (D and E) were determined after five weeks of treatment. Images in (D) are representative
pictures of ORO staining in the examined tissue (20 × magnification, bar represents 150 μm). Data is shown as mean ± s.e.m. A * denotes a
significant (p < 0.05) effect of corticosterone treatment and a # denotes a significant effect of liraglutide.
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obesity and ectopic fat deposition in liver that otherwise
occurs during administration of corticosterone to mice.
Liraglutide improves glucose tolerance in
corticosterone-treated mice
To investigate the effects of liraglutide on glucose control
in corticosterone-treated mice, serum insulin and blood
glucose levels were measured every week in random-fed
mice throughout the study period. Corticosterone given
via the drinking water time-dependently increased serum
insulin levels (Figure 2A) as compared to vehicle-treated
mice, indicating reduction of peripheral insulin sensi-
tivity. Liraglutide attenuated circulating insulin levels
by approximately 35% in corticosterone-treated mice
(Figures 2A and B). Administration of corticosterone via
the drinking water did not induce fasting hyperglycemia.
The fasting blood glucose levels after five weeks of treat-
ment were 8.1 ± 0.7 mmol/L and 9.0 ± 1.4 mmol/L invehicle and corticosterone treated mice, respectively (not
significant). In contrast, mice treated with corticosterone
demonstrated impaired glucose control in the fed state.
After two weeks of treatment with corticosterone, blood
glucose levels in random-fed mice were significantly
higher as compared to vehicle-treated mice and after three
weeks of treatment the blood glucose levels were above
20 mmol/L in corticosterone-treated mice (Figure 2C).
Once-daily injections of liraglutide improved glucose con-
trol in mice exposed to corticosterone. Fed blood glu-
cose levels were normal in mice receiving liraglutide in
combination with corticosterone up until the third week
of treatment (Figure 2C). Integrated over the total five
week study period the GLP-1R agonist reduced hypergly-
cemia in random fed mice by 30% (Figure 2D). However,
after five weeks of GC exposure liraglutide was no longer
able to prevent the hyperglycemia in this cohort of mice.
To further evaluate the effects of liraglutide on glucose
control in corticosterone-exposed mice we performed an
Table 1 Serum parameters in mice
Experimental groups
Vehicle/PBS GC/PBS Vehicle/Lira GC/Lira
Corticosterone (ng/ml) 6.72 ± 2.29 46.56 ± 4.78* 7.83 ± 2.18 65.29 ± 10.6*
Corticotropin (pg/ml) 122 ± 14 45 ± 8* 134 ± 18 39 ± 14*
NEFA (mmol/L) 0.86 ± 0.04 1.30 ± 0.11* 0.92 ± 0.07 1.22 ± 0.14
Cholesterol (mmol/L) 2.84 ± 0.19 5.29 ± 0.46* 2.61 ± 0.12 4.16 ± 0.68*
Triglycerides (mmol/L) 1.26 ± 0.06 4.13 ± 1.10* 1.39 ± 0.15 2.98 ± 0.75
Male C57Bl/6J mice were treated with 1% ethanol (vehicle) or 100 μg/ml corticosterone (GC) via their drinking water together with once-daily injections of either
PBS or liraglutide (Lira) at a final dose of 0.3 mg per kg body weight for five consecutive weeks (n = 5-6). At the end of the study, blood was collected by heart
puncture and serum was obtained. Serum levels for the indicated parameters are shown as mean ± s.e.m. A * denotes a significant (p < 0.05) effect of
corticosterone treatment.
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ment, respectively. Treatment with corticosterone sig-
nificantly reduced the blood glucose lowering effect of
insulin (Figures 3A and B [B is AUC]). Treatment
with liraglutide neither influenced insulin sensitivity
in corticosterone- nor in vehicle-treated animals. Following
IPGTT, glucose tolerance was reduced in corticosterone-
treated mice as compared to vehicle-treated mice
(Figures 3C and D [D is AUC]). Once daily injectionsFigure 2 Once daily injections of liraglutide delay hyperinsulinemia a
mice were treated with 1% ethanol (white squares and circles or white bar
via the drinking water together with once-daily injections of either PBS (sq
body weight (circles or striped bars) for five consecutive weeks (n = 6). Seru
determined every week in random-fed animals. Data is shown as mean ± s
treatment and a # denotes a significant effect of liraglutide.of liraglutide significantly improved glucose tolerance
in both vehicle- and corticosterone-treated animals, with
the largest effect obtained in corticosterone-treated mice
(Figures 3C and D). C-peptide levels during the IPGTT
were analyzed, showing that before glucose injection both
cohorts of corticosterone-treated mice had higher levels
of C-peptide as compared to their respective control
groups, which reflects the higher basal insulin levels
(Figure 3E). During the in vivo GSIS (IPGTT), thend hyperglycemia in corticosterone-exposed mice. Male C57Bl/6J
s) or 100 μg/ml corticosterone (black squares and circles or black bars)
uares or unstriped bars) or liraglutide at a final dose of 0.3 mg per kg
m insulin levels (A and B) and blood glucose levels (C and D) were
.e.m. A * denotes a significant (p < 0.05) effect of corticosterone
Figure 3 Once daily injections of liraglutide do not affect insulin sensitivity but improve glucose tolerance in corticosterone-exposed
mice. Male C57Bl/6J mice were treated with 1% ethanol (white squares and circles or white bars) or 100 μg/ml corticosterone (black squares and
circles or black bars) via the drinking water together with once-daily injections of either PBS (squares or unstriped bars) or liraglutide at a final
dose of 0.3 mg per kg body weight (circles or striped bars) for five consecutive weeks (n = 6). After four weeks of treatment insulin sensitivity was
determined via an IPinsTT (A and B) and after five weeks of treatment glucose tolerance was determined via an IPGTT (C and D). During the
IPGTT serum samples were collected and C-peptide levels were measured (E). Data is shown as mean ± s.e.m. A * denotes a significant (p < 0.05)
effect of corticosterone treatment and a # denotes a significant effect of liraglutide.
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ing corticosterone, 33 ± 6% above basal at 15 minutes
and 65 ± 17% above basal at 30 minutes post glucose
injection (Figure 3E). In contrast, the glucose-stimulated
increase in serum C-peptide levels in mice treated with
corticosterone and liraglutide was 149 ± 30% and 178 ±
23% above basal at 15 minutes and 30 minutes post glu-
cose injection, respectively, indicating an improvement of
beta-cell responsiveness to glucose by liraglutide treat-
ment (Figure 3E).Liraglutide has no effect on the increased beta-cell mass
induced by corticosterone
To investigate possible structural changes in the endo-
crine pancreas in the present insulin-resistant mice
model, we determined the beta- and alpha-cell masses in
histological sections of pancreatic glands taken after five
weeks of treatment with or without corticosterone in the ab-
sence or presence of liraglutide. The total pancreas weight
was not altered among the groups (data not shown) nor
was there any significant difference between the groups in
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and B). Instead there was an apparent islet hypertrophy in
both groups of corticosterone-treated mice (Figure 4A).
Morphometric analysis revealed that the relative and abso-
lute beta-cell mass was significantly increased in pancreata
obtained from corticosterone-treated mice irrespective
of whether they were co-treated with liraglutide or not
(Figures 4C-E). This increase in beta-cell mass is explainedFigure 4 Once daily injections of liraglutide do not affect the increme
mice. Male C57Bl/6J mice were treated with 1% ethanol (vehicle, white ba
together with once-daily injections of either PBS (unstriped bars) or liraglut
for five consecutive weeks (n = 5-6). After treatment the pancreatic glands
immunostained for insulin-positive cells (A). Morphometric analysis was use
absolute beta-cell mass either expressed in mg (D) or as μg per g body we
the examined tissue (40 × magnification, bar represents 500 μm). Data is sh
corticosterone treatment.by enhanced islet-cell proliferation (most likely beta-cell
proliferation) in corticosterone-treated mice. Figure 5A
shows a higher distribution of Ki67-positive nuclei in both
corticosterone-treated groups compared with their re-
spective control groups. The islet-cell proliferation ex-
panded significantly, reaching 2.6- and 2.4-fold increase in
mice receiving corticosterone in the absence or presence
of liraglutide treatment, respectively, compared to theirnt of pancreatic beta-cells mass seen in corticosterone-exposed
rs) or 100 μg/ml corticosterone (GC, black bars) via the drinking water
ide (Lira) at a final dose of 0.3 mg per kg body weight (striped bars)
were dissected and processed for histology. Tissue sections were
d to determine islet density (B), relative beta-cell mass (C) and
ight (E). Images in (A) are representative pictures of insulin staining in
own as mean ± s.e.m. A * denotes a significant (p < 0.05) effect of
Figure 5 Once daily injections of liraglutide do not affect beta-cell proliferation in corticosterone-exposed mice. Male C57Bl/6J mice
were treated with 1% ethanol (vehicle, white bars) or 100 μg/ml corticosterone (GC, black bars) via the drinking water together with once-daily
injections of either PBS (unstriped bars) or liraglutide (Lira) at a final dose of 0.3 mg per kg body weight (striped bars) for five consecutive weeks
(n = 5-6). After treatment the pancreatic glands were dissected and processed for histology. Tissue sections were immunostained for Ki67-positive
cells (A, red arrow). Morphometric analysis was used to the percentage of beta-cells that stained positive for Ki67 in the different mice cohorts
(B). Images in (A) are representative pictures of Ki67 staining in the examined tissue (400 × magnification, bar represents 50 μm). Data is shown
as mean ± s.e.m. A * denotes a significant (p < 0.05) effect of corticosterone treatment.
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mass in histological sections of pancreata taken after five
weeks of treatment, with or without corticosterone in the
absence or presence of liraglutide, showed a significant
increase in alpha-cell mass in corticosterone-treated
mice (Figure 6). Liraglutide per se had no significant effect
on any of the alpha-cell parameters evaluated, but seemed
to cause a partial attenuation in the corticosterone-induced
expansion of alpha-cell mass. Altogether, these data demon-
strate that corticosterone administration to mice inducesexpansion of beta-cell and alpha-cell masses. Liraglutide
exerted no positive or negative effect upon beta-cell mass
per se or when combined with corticosterone. For alpha-
cell mass, however, liraglutide treatment seems to re-
sult in a partial attenuation of the absolute alpha-cell mass
expansion caused by corticosterone treatment.
Discussion
The main finding in this paper is that once daily injections
with the DPP-4-resistant GLP-1R agonist liraglutide delay
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function in a mouse model of GC-induced metabolic
syndrome. In this model, corticosterone is administrated
via the drinking water. The model recapitulates in many
respects the metabolic syndrome in humans, including
body weight gain, dyslipidemia, ectopic lipid deposition
and hypertension that occurs in conjunction with insu-
lin resistance and glucose intolerance [20,21]. It should,
however, be noted that – after five weeks of treatment
with corticosterone – the mice became catabolic as evi-
dent by reduced body weight and that liraglutide was not
able to fully protect against the diabetogenic effects of the
GC in this setting. Thus, liraglutide fell short in providing
full protection against corticosterone-induced glucose tol-
erance which of course limits the value of this study.
Nevertheless, it is clear that liraglutide postponed the
appearance of obesity, hyperinsulinemia and hypergly-
cemia. It is also clear that administration of the GLP-1R
agonist improved glucose clearance in an IPGTT. We
could exclude the possibility that liraglutide caused any
general reduction in peripheral GC sensitivity, as there
were neither any differences between the effect of cor-
ticosterone on the glucose decay during the insulin tol-
erance test nor any impact of liraglutide on the reduced
spleen size incurred by GC treatment. As nausea and
vomiting are reported side effects during liraglutide
treatment [28], this would be a potentially confounding
factor in this study. However, we took care to avoid
these side effects by slowly increasing the dosage until
the final dose of liraglutide was reached and as indicated
by the similar food intake in liraglutide-exposed mice as
compared to mice treated with corticosterone or vehicle
this dosing regime was successful. Liraglutide has previ-
ously been shown to efficaciously curb glucose intolerance
and diabetes in both animal models [29] and in human
T2DM patients [30]. However, its potential to counteract
the diabetogenic effects of long-term steroid treatment
has not previously been rigorously tested. Our findings
show that liraglutide can delay hyperglycemia and avoid
glucose intolerance that otherwise occurred as a conse-
quence of steroid treatment. Thus, liraglutide may confer
treatment benefits in patients at increased risk of de-
veloping steroid-induced diabetes. Liraglutide treatment
was initiated simultaneously to corticosterone and our data
supports that such an approach should be considered
when handling patients with susceptibility towards steroid-
induced diabetes, like subjects with a priori known insulin
resistance [31], low insulin secretion capacity [12,32], gen-
etic predisposition [33], or in patients with obesity [34].
Our findings support a recent case report where exenatide
(another GLP-1R agonist) improved glucose control in pa-
tients with T2DM with worsened glycemic control caused
by GC therapy [17], and yet another randomized, placebo-
controlled, double-blind, crossover exploratory study ineight healthy men where it was shown that exenatide pre-
vented GC-induced glucose intolerance and islet dysfunc-
tion [16]. However, we think that the experimental data
presented here advances the field in several aspects. First,
the GC exposure time used in this study is extended to last
for several weeks and in this aspect it better mimics the
treatment time for patients prescribed GC-based drugs.
Second, we show that once-daily injections with the DPP-
4-reistant GLP-1R agonist liraglutide can improve glycemic
control in this model. Finally, as will be discussed below,
we discriminate between two aspects of beta-cell adapta-
tion to GC induced insulin resistance. Liraglutide treat-
ment may also reduce stress responses in rodents [35], an
effect that can contribute to the anti-diabetic observed in
our study.
This study also reports on the ability of liraglutide
to counteract GC-induced obesity. As expected, ab-
dominal obesity developed in corticosterone-treated
mice. Importantly, liraglutide delayed weight gain in
corticosterone-treated mice, which was associated with
reduced epididymal fat mass. A role of GLP-1 in obesity
pathophysiology was suggested already in 1983 when it
was shown that L-cell secretory activity was reduced in
morbidly obese subjects [36]. Furthermore, obese patients
with reduced post-prandial GLP-1 secretion displayed
improved GLP-1 secretory activity upon weight loss [37].
This may be a consequence of lipotoxic actions directed
towards the L-cells as these cells succumb by lipoapopto-
sis when exposed to palmitate in culture [38]. As GC ther-
apy specifically induced visceral obesity, which is much
more prone to induce insulin resistance than subcutane-
ous adiposity, it is additionally important that, as showed
herein, liraglutide delays the progression towards obesity
that otherwise relentlessly occurs during long-term GC
treatment. These findings are in concordance with those
reported in the LEAD (Liraglutide Effect and Action in
Diabetes) studies series, where the weight loss after 30
week to 52 week treatment with liraglutide was 2–3 kg
more than placebo treatment [39-44]. The weight loss oc-
curred in the ratio 2:1 between fat and lean tissue, and the
relative weight loss was greater in visceral fat compared
with subcutaneous adipose tissue [45]. Also hepatic stea-
tosis was reduced in patients during treatment with lira-
glutide [45], which supports our findings with decreased
liver neutral lipid content in corticosterone-treated mice
receiving liraglutide.
The present study also investigates the plasticity of the
pancreatic beta-cell and alpha-cell mass in this setting of
GC excess. There is a strong correlation between insulin
sensitivity and insulin secretion such that reduced insulin
sensitivity leads to augmented insulin secretion in order to
maintain glucose control [21]. Compensatory hyperinsuli-
nemia in response to GC-induced reduction of insulin
sensitivity may be attributable to increased beta-cell
Figure 6 Corticosterone-exposed mice display increased alpha-cell mass. Male C57Bl/6J mice were treated with 1% ethanol (white bars) or
100 μg/ml corticosterone (GC, black bars) via the drinking water together with once-daily injections of either PBS (unstriped bars) or liraglutide
(Lira) at a final dose of 0.3 mg per kg body weight (striped bars) for five consecutive weeks (n = 5-6). After treatment, the pancreatic gland was
dissected and processed for histology. Tissue sections were immunostained for glucagon-positive cells (A). Morphometric analysis was used to
determine relative alpha-cell mass (B) and absolute alpha-cell mass either expressed in mg (C) or as μg per g body weight (D). Images in (A) are
representative pictures of glucagon staining in the examined tissue (100 × magnification, bar represents 200 μm). Data is shown as mean ± s.e.m.
A * denotes a significant (p < 0.05) effect of corticosterone treatment.
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[24,28]. In response to corticosterone treatment the beta-
cell mass increased as a consequence, at least in part, of
enhanced beta-cell proliferation. This observation is in
agreement with the well-established reciprocal relationshipbetween insulin sensitivity and pancreatic islet function. As
insulin sensitivity decreases, the insulin secretion initially
and adaptively increases in order to maintain the control
of glucose homeostasis [46]. The compensatory increase of
circulating insulin in response to the GC-imposed insulin
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includes augmented beta-cell function [47] and/or
beta-cell mass [48]. Mice treated with corticosterone
and liraglutide had the same impairment of insulin sen-
sitivity as indicated by their similar capacity to clear
glucose after an injection with insulin (Figures 3A and
B). Mice treated with corticosterone with or without
liraglutide also displayed the same increase in beta-cell
mass (Figure 4), indicating that the beta-cell mass is
primarily a reflection of the prevailing reduced insulin
sensitivity and that liraglutide is not predominantly tar-
geting insulin sensitivity.
An increased beta-cell mass in corticosterone-treated
mice seems to be sufficient to maintain fasting normo-
glycemia, since this parameter was not affected after five
weeks of treatment with the steroid. In the fed state,
however, the insulin secretion in response to food intake
was not enough to avoid the appearance of hypergly-
cemia, despite the higher beta-cell mass observed in
corticosterone-treated groups. Liraglutide had no effect
on beta-cell mass but displayed a marked ability to im-
prove glucose clearance in response to a glucose chal-
lenge (IPGTT, Figure 3). These observations point
towards an acute effect of liraglutide so that the optimal
response to glucose challenge in both groups of mice
treated with liraglutide is explained by short-term lir-
aglutide effects. Our finding of augmented glucose-
stimulated C-peptide secretion in liraglutide-treated
mice indicates a direct acute effect on pancreatic beta-
cells that may turn beta-cells more competent to sense
glucose. A puzzling observation is that liraglutide
improved glucose tolerance also in vehicle-treated
mice despite similar insulin sensitivity and glucose-
stimulated C-peptide secretion. Since C-peptide clear-
ance occurs mainly through renal mechanisms, and
GLP-1 is known to positively impact renal function
[49] we cannot exclude that increased insulin secretion
may have been masked by increased renal clearance of
C-peptide. Thus, the positive effects of liraglutide on
glucose tolerance in this model of metabolic syndrome
are best described by a direct effect on pancreatic beta-
cells that seems to promote augmented exocytosis
rather than promoting beta-cell proliferation and/or
acting on peripheral insulin action. This means that lir-
aglutide would be most effective if given at an early
stage of T2DM when beta-cell mass is preserved. A re-
cent publication reported on a positive association be-
tween incretin-based therapy and an expansion of
pancreatic alpha-cell mass [50] in human post mortem
specimens. However, we did not observe any increase
in alpha-cell following 5 weeks of liraglutide treatment.
In fact, liraglutide reduced the induction of alpha-cell
mass seen in corticosterone-treated mice, although this
finding did not reach statistical significance.Conclusions
In this paper we show that the GLP-1R agonist liraglu-
tide delays progression towards obesity and prandial
hyperglycemia and efficiently enhances in vivo GSIS in a
mouse model of GC-induced metabolic syndrome. Thus,
GLP-1R agonists may offer advantages for patients suf-
fering from steroid diabetes or glucose intolerance as a
side effect of long-term GC therapy.
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